GlassScriptPhysician profile
Subroto Bhattacharya
NPI 1053341685
$11,812.95
in general payments reported to CMS, 2019-2025
59 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $1,176 · 2021: $1,557 · 2022: $1,582 · 2023: $1,792 · 2024: $2,479 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,546 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,546.18 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,268.33 | 2021-2025 | Vraylar, Qulipta, Botox |
| Astrazeneca Pharmaceuticals LP | $1,144.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lundbeck LLC | $964.94 | 2022-2025 | Rexulti |
| Pfizer INC. | $860.10 | 2019-2025 | |
| Novo Nordisk INC | $762.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $701.23 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $667.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $540.08 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $406.37 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $353.97 | 2019-2025 | Trintellix |
| Neos Therapeutics, LP | $337.83 | 2019-2021 | |
| Corium, LLC | $277.73 | 2022-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $262.85 | 2025 | Jornay Pm |
| Amgen INC. | $259.81 | 2019-2024 | Repatha, Otezla, Prolia |
| Vanda Pharmaceuticals INC. | $247.77 | 2020-2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $208.47 | 2019-2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.16 | 2022-2025 | Caplyta |
| Inspire Medical Systems, INC. | $179.62 | 2024-2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $155.47 | 2022-2025 | Rexulti |
| Harmony Biosciences LLC | $147.42 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.09 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $141.08 | 2019-2025 | Gardasil 9, M-M-R II, Vaxelis |
| Sanofi-Aventis U.S. LLC | $138.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $134.45 | 2021-2025 | |
| Boston Scientific Corporation | $114.95 | 2024-2025 | General - Therapies |
| Antares Pharma, INC. | $84.31 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $80.62 | 2023-2024 | Freestyle Libre 3, Eterna |
| Ultragenyx Pharmaceutical INC. | $77.63 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $76.27 | 2023-2024 | Ingrezza |
| Baxter Healthcare | $64.29 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Digital Macroview Otoscope |
| Dexcom, INC. | $55.04 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $52.64 | 2019-2022 | |
| Halozyme INC | $52.37 | 2023 | |
| Eisai INC. | $46.75 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $43.99 | 2021 | |
| Exact Sciences Corporation | $41.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $39.22 | 2023 | Quviviq |
| Galderma Laboratories, L.P. | $35.88 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.20 | 2019-2024 | Eliquis |
| Sumitomo Pharma America, INC. | $32.53 | 2025 | Gemtesa |
| Tolmar, INC. | $28.60 | 2025 | Jatenzo |
| Echosens North America, INC. | $28.60 | 2024-2025 | Fibroscan, Fibroscan |
| Biohaven Pharmaceuticals, INC. | $28.57 | 2021 | |
| Heartflow, INC. | $28.08 | 2024 | |
| Organon LLC | $27.88 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $25.63 | 2025 | Dupixent |
| Verona Pharma, INC. | $23.09 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $22.07 | 2023 | Auvelity |
| Phadia US INC. | $21.08 | 2021 | |
| Viatris Specialty LLC | $19.51 | 2025 | Yupelri |
| Dermira, INC. | $18.75 | 2020 | |
| Genentech USA, INC. | $18.44 | 2020 | |
| Shield Therapeutics INC | $18.41 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $17.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.11 | 2022 | |
| Currax Pharmaceuticals LLC | $14.71 | 2025 | Contrave |
| Seqirus USA INC | $14.23 | 2024 | Fluad, Flucelvax |
| Allergan, INC. | $12.75 | 2020 | |
| Phathom Pharmaceuticals, INC. | $3.62 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subroto Bhattacharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.